An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers

Titre officiel

A Phase I Study of BMS-986301 Monotherapy and Combination Therapy With Nivolumab and Ipilimumab in Participants With Advanced Solid Cancers

Sommaire:

The main purpose of this study is to characterize the safety, tolerability, dose limiting toxicities, maximum tolerated dose, maximum administered dose, or alternative dose of BMS-986301 alone or in combination with nivolumab and ipilimumab to participants with cancers that have failed to respond to or are known to be insensitive to T cell checkpoint inhibiting antibodies.

Description de l'essai

Primary Outcome:

  • Number of Participants With Dose-Limiting Toxicities (DLTs)
  • Number of Participants With an Adverse Event
  • Number of Participants With a Serious Adverse Event
  • Number of Participants With an AE leading to discontinuation of study treatment
  • Number of Deaths
  • Number of clinically significant changes in lab assessment of Blood
  • Number of clinically significant changes in lab assessment of Blood Serum
  • Number of clinically significant changes in lab assessment of Urine
Secondary Outcome:
  • Maximum Observed Plasma Concentration (Cmax) of BMS - 986301 in Plasma
  • Maximum Observed Plasma Concentration (Cmax) of BMS - 986301 in Urine
  • Time to Reach Maximum Observed Plasma Concentration (Tmax) of BMS - 986301 in Plasma
  • Time to Reach Maximum Observed Plasma Concentration (Tmax) of BMS - 986301 in Urine
  • Area under the concentration-time curve in one dosing interval (24 h) of BMS - 986301 in Plasma
  • Area under the concentration-time curve in one dosing interval (24 h) of BMS - 986301 in Urine
  • Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] of BMS - 986301 in Plasma
  • Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] of BMS - 986301 in Urine
  • Change from Baseline in Levels and Activation of Tumour Infiltrating T Cells
  • Change from baseline in Programmed Death-Ligand 1 (PD-L1) Expression Status in Tumours
  • Change from Baseline in Blood Cytokines
  • Change from Baseline in Peripheral Blood Mononuclear Cell (PBMC) gene expression
  • Change from Baseline in Genetic Expression Profile (GEP) in injected and non-injected tumours

Voir cet essai sur ClinicalTrials.gov

Intéressé(e) par cet essai?

Imprimez cette page et apportez-la chez votre médecin pour discuter de votre admissibilité à cet essai et des options de traitement. Seul votre médecin peut vous recommander pour un essai clinique.

Ressources

Société canadienne du cancer

Ces ressources sont fournies en partenariat avec Société canadienne du cancer